Author

M. Stuible

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Assay:protein sequence· 2 Assay:proteomics· 2 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

Y. Durocher· 5 shared A. Tran· 2 shared C. Gervais· 2 shared D. Duque· 2 shared S. Perret· 2 shared A. Gamarnik· 1 shared A. Lametti· 1 shared A. Wigdorovitz· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

Y. Durocher

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective againstOmicron

D. Bottero, E. Rudi, P. M. Aispuro, M. E. Zurita, M. E. Gaillard, M. M. G. L. Ledesma, J. Malito, M. Stuible, N. M. Ambrosis, Y. Durocher, A. Gamarnik, A. Wigdorovitz, D. Hozbor

This study evaluates the effectiveness of heterologous booster vaccines against Omicron BA.1 using a mouse model, showing that mRNA-based vaccines outperform vector-based ones, while heterologous boosters improve immune responses.

bioRxiv · Oct 5, 2023Immunology

BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine

D. J. Perera, P. Domenech, G. G. Babuadze, M. Naghibosadat, F. Alvarez, C. Koger-Pease, L. Labrie, M. Stuible, Y. Durocher, C. A. Piccirillo, A. Lametti, P. O. Fiset, S. M. Elahi, G. P. Kobinger, R. Gilbert, , M. Ndao

BCG enhances anti-SARS-CoV-2 immunity and protection afforded by a novel adenovirus-vectored vaccine.

bioRxiv · Mar 21, 2023Immunology

Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & Hamsters

F. C. Stark, B. Akache, L. Deschatelets, A. Tran, M. Stuible, Y. Durocher, M. J. McCluskie, G. Agbayani, R. Dudani, B. A. Harrison, T. M. Renner, S. R. Makinen, J. Bavananthasivam, D. Duque, C. D. Zarley, , J. Zimmermann

This study evaluates an intranasal vaccine formulation containing a proteosome-adjuvanted SARS-CoV-2 Spike protein, showing immunogenicity and efficacy in mice and hamsters against multiple variants.

bioRxiv · Mar 2, 2022 · PreprintImmunology

Arsenal of Nanobodies for Broad-Spectrum Countermeasures against Current and Future SARS-CoV-2 Variants of Concerns

M. A. Rossotti, H. van Faassen, A. Tran, J. Sheff, J. A. Sandhu, D. Duque, M. Hewitt, S. Wen, R. Bavananthasivam, S. Beitari, K. Matte, G. Laroche, P. M. Giguere, C. Gervais, M. Stuible, , J. Tanha

This paper presents a diverse set of nanobodies targeting SARS-CoV-2 spike glycoprotein with broad neutralization activity against multiple variants and high in vivo efficacy.

bioRxiv · Dec 20, 2021 · PreprintBioengineering

Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells

M. Stuible, C. Gervais, S. Lord-Dufour, S. Perret, D. L'Abbe, J. Schrag, G. St-Laurent, Y. Durocher

The paper develops a method to rapidly produce high-yield, full-length SARS-CoV-2 spike protein using CHO cells and reports yields of 100-150 mg/L.

bioRxiv · Sep 8, 2020Bioengineering